ICU Medical, Inc. - 10-Q Filing Summary
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for ICU Medical, Inc., a manufacturer of medical products including needleless connectors (CLAVE), custom I.V. systems, and drug delivery valves. The report covers the quarterly period ended June 30, 2001, and the six-month period ended on the same date. The company is headquartered in San Clemente, California.
Key Financial Metrics
| Metric | Q2 2001 | Q2 2000 | YTD 2001 | YTD 2000 |
|---|---|---|---|---|
| Net Sales | $16,952,000 | $13,623,000 | $31,958,000 | $27,872,000 |
| Gross Profit | $10,061,000 | $7,843,000 | $18,610,000 | $16,073,000 |
| Gross Margin | 59% | 58% | 58% | 58% |
| Net Income | $3,764,000 | $2,970,000 | $7,297,000 | $5,842,000 |
| Diluted EPS | $0.39 | $0.33 | $0.77 | $0.66 |
| Cash & Equivalents | $3,354,000 | N/A | $3,354,000 | N/A |
| Liquid Investments | $56,541,000 | N/A | $56,541,000 | N/A |
| Total Current Assets | $77,516,000 | N/A | $77,516,000 | N/A |
| Total Current Liabilities | $8,910,000 | N/A | $8,910,000 | N/A |
| Operating Cash Flow (YTD) | N/A | N/A | $7,892,000 | $9,741,000 |
Note: All dollar amounts in thousands except per share data. The company reported no long-term debt in the balance sheet liabilities section.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 24% in Q2 2001 and 15% YTD compared to the prior year. This was driven primarily by a 26% increase in CLAVE product sales and a 54% increase in custom I.V. systems unit sales.
- Profitability: Net income rose 27% in Q2 and 25% YTD. Operating income increased 32% in Q2, aided by higher gross profit and controlled operating expense growth.
- Customer Concentration: Sales to major distributors Abbott Laboratories and B. Braun Medical Inc. remained significant. Abbott sales increased slightly, while B. Braun sales (including revenue sharing) increased significantly due to higher CLAVE volume, though revenue sharing payments declined.
- Cost Pressures: Average selling prices for CLAVE products decreased approximately 17% year-over-year due to market competition. However, this was offset by increased volume and lower unit production costs.
- Utility Costs: Electrical energy costs in California remained elevated (approx. 3x Q1 2000 levels), though they moderated slightly in Q2 2001 compared to Q1 2001.
Guidance, Outlook, and Risks
- Outlook: Management expects sales to continue growing in 2001. However, they anticipate gross margins may decline slightly due to continued price erosion and a higher mix of labor-intensive custom I.V. systems.
- Strategic Initiatives: The company is expanding its custom I.V. systems business (including a new agreement with Abbott for "SetSource") and launched "SetFinder" to distribute standard I.V. sets online, though SetFinder sales remain insignificant.
- Capital Expenditures: Expected to be between $4 million and $6 million in 2001 for production tooling and capacity expansion.
- Legal Risks: The company is involved in patent litigation with Medex, Inc. and Porex Medical Products, Inc. regarding CLAVE and CLC2000 products. It is also in a contractual dispute with B. Braun Medical Inc. Management believes these suits are without merit but notes the uncertainty.
- Market Risks: Significant dependence on a small number of customers (Abbott, B. Braun). Continued shift in the market toward needleless technology may reduce sales of protected needle products. Uncertainty regarding future electricity costs and availability in California.
Investor Verification Checklist
- Customer Concentration: Verify the stability of contracts with Abbott and B. Braun, which represent a large portion of revenue.
- Price Erosion: Monitor the trend of average selling prices for CLAVE products against volume growth to ensure margin sustainability.
- Legal Proceedings: Track the status of patent litigation with Medex and Porex, as adverse rulings could impact core product sales.
- Utility Costs: Assess the impact of California energy market volatility on future operating costs.
- New Product Adoption: Evaluate the success of the new custom I.V. systems and the CLC2000 in offsetting declines in legacy products like the Rhino and protected needles.